Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment
- PMID: 29114295
- PMCID: PMC5652107
- DOI: 10.4103/ajns.AJNS_39_15
Tumor Recurrence in a Glioblastoma Patient after Discontinuation of Prolonged Temozolomide Treatment
Abstract
There is no consensus regarding the duration of temozolomide (TMZ) treatment for glioblastoma multiforme (GBM). We report a 53-year-old woman who had a left frontal GBM. The tumor showed good response to TMZ treatment, which was discontinued after 5.5 years with recurrence of tumor at the posterior fossa 6 months later, although there was no definite tumor recurrence in the left frontal region. The tumor failed to respond to the reinstitution of TMZ therapy. Continuous TMZ treatment may be necessary in GBM patients on prolonged TMZ treatment despite improved neurological condition and imaging studies revealing marked tumor regression.
Keywords: Glioblastoma; temozolomide; tumor recurrence.
Conflict of interest statement
There are no conflicts of interest.
Figures
References
-
- Brandes AA, Tosoni A, Franceschi E, Sotti G, Frezza G, Amistà P, et al. Recurrence pattern after temozolomide concomitant with and adjuvant to radiotherapy in newly diagnosed patients with glioblastoma: Correlation with MGMT promoter methylation status. J Clin Oncol. 2009;27:1275–9. - PubMed
-
- Hart MG, Grant R, Garside R, Rogers G, Somerville M, Stein K. Temozolomide for high grade glioma. Cochrane Database Syst Rev. 2008;8:CD007415. - PubMed
-
- Hau P, Koch D, Hundsberger T, Marg E, Bauer B, Rudolph R, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-grade glioma. Neurology. 2007;68:688–90. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources
